Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly

Li, Wen; Hu, Xiurong; Hu, Qinglian; Shen, Jie; Xu, Jin; Zhou, Jun; Tang, Guping; Chu, Paul K.

doi:10.1016/j.biomaterials.2012.05.060

Cited by 115 publications

(94 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 Hu et al have found survivin short hairpin RNA to treat ovarian cancer and also suppress the expression of survivin. 36 Mehta et al have proved that YM155, a small molecule, could specifically inhibit survivin gene expression by suppressing its promoter activity, which has been proved to inhibit esophageal squamous-cell carcinoma growth in mice. 37 In addition, dominant-negative mutant was another method of choice to suppress the antiapoptotic function of survivin.…”

Section: Discussionmentioning

confidence: 99%

Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

Luo

Zhao

et al. 2016

IJN

View full text Add to dashboard Cite

Gene therapy has promising applications in ovarian cancer therapy. Blocking the function of the survivin protein could lead to the growth inhibition of cancer cells. Herein, we used degradable heparin–polyethyleneimine (HPEI) nanoparticles to deliver a dominant-negative human survivin T34A (hs- T34A ) gene to treat ovarian cancer. HPEI nanoparticles were characterized and were found to have a dynamic diameter of 66±4.5 nm and a zeta potential of 27.1±1.87 mV. The constructed hs- T34A gene expression plasmid could be effectively delivered into SKOV3 ovarian carcinoma cells by HPEI nanoparticles with low cytotoxicity. Intraperitoneal administration of HPEI/hs- T34A complexes could markedly inhibit tumor growth in a mouse xenograft model of SKOV3 human ovarian cancer. Moreover, according to our results, apparent apoptosis of cancer cells was observed both in vitro and in vivo. Taken together, the prepared HPEI/hs- T34A formulation showed potential applications in ovarian cancer gene therapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

Luo

Zhao

et al. 2016

IJN

View full text Add to dashboard Cite

show abstract

“…The TMV-b-CD/Ada-FA/Ada-Dox particles afforded comparable therapy efficiency of free Dox towards HepG2 cells, confirming the potential for sustained release of Dox due to the dissociation of the b-CD/Ada supramolecular structure. 31,32 In summary, we have demonstrated here a supramolecular strategy based on the interaction between b-CD and Ada moieties. Using this method, multifunctional TMV particles have been constructed in a facile manner to load with imaging agents, targeting ligands, and chemotherapeutic drugs, which could potentially be used in therapeutic and diagnostic applications.…”

mentioning

confidence: 81%

“…S7, ESI †), similar to the literature reports. 31,32,36 To investigate the selective targeting ability of Dox-loaded TMV, HepG2 tumor cells (folate receptor positive) and NIH-3T3 fibroblast cells (folate receptor negative) were treated with TMV-b-CD/ Ada-Dox, TMV-b-CD/Ada-FA/Ada-Dox and free Dox. Cellular uptake and cell proliferation were evaluated by confocal laser scanning microscopy and cell viability assay, respectively.…”

mentioning

confidence: 99%

A supramolecular strategy to assemble multifunctional viral nanoparticles

et al. 2013

View full text Add to dashboard Cite

“…[75] First, plasmid DNA was complexed with this PEI-cyclodextrin nano-platform through electrostatic interactions, and adamantine-conjugated DOX was inserted into the cavity of cyclodextrin through host-guest interaction. [75a] The obtained DOX/DNA co-delivery system could release DOX in response to pH decrease and achieve efficient gene transfection in a cooperative manner.…”

Section: Pei-based Nanoparticles With Other Nanostructuresmentioning

confidence: 99%

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

Thambi

Lee

2017

Adv Healthcare Materials

107

View full text Add to dashboard Cite

Drug and gene delivery systems based on nanoparticles, microparticles and hydrogels have been widely studied for cancer treatment in the past decade. To achieve an efficient and safe delivery, selection of drug and gene delivery carrier is critical. Biocompatible polymeric nanoparticles are considerably promising carrier candidates in delivery of drugs and genes because of their unique chemical and physical properties. However, delivery of a drug or gene sometimes cannot achieve a satisfactory treatment effect. Therefore, co‐delivery of dual drugs or co‐delivery of a drug and a gene in a polymeric nanoparticle has attracted attention. Such co‐delivery systems can overcome multi‐drug resistance of chemical drugs and achieve a synergistic therapeutic effect. In this progress report, we summarize recent progress in the preparation and application of polymeric drug and gene co‐delivery nanosystems. The remaining challenges and future trends in this field are also included.

show abstract

Synergistic treatment of ovarian cancer by co-delivery of survivin shRNA and paclitaxel via supramolecular micellar assembly

Cited by 115 publications

References 30 publications

Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

Efficient inhibition of ovarian cancer by degradable nanoparticle-delivered survivin T34A gene

A supramolecular strategy to assemble multifunctional viral nanoparticles

Co‐Delivery of Drugs and Genes Using Polymeric Nanoparticles for Synergistic Cancer Therapeutic Effects

Contact Info

Product

Resources

About